-
NUMBER OF INSIDER BUYING
(Last 12 Months)
0 -
NUMBER OF INSIDER SELLING
(Last 12 Months)
6 -
AMOUNT OF INSIDERS BUYING
(Last 12 Months)
$0 -
AMOUNT OF INSIDERS SELLING
(Last 12 Months)
$6.21 M
AN2 Therapeutics, Inc. Insider Transactions
AN2 Therapeutics, Inc. Insider Trades History
| Insider Name | Buy/Sell | Shares Bought/Sold @ Price |
Total Transaction | Shares Held After Transaction |
Transaction Date | Filing Date | Details |
|---|---|---|---|---|---|---|---|
|
Zakrzewski Joseph S
Director |
Sell | 100,000 @ $19.11 | $1.91 M | 405,880 | 01/18/2024 | 01/19/2024 | |
|
Aziz Kabeer
Director |
Sell | 84,093 @ $19.65 | $1.65 M | 1,995,958 | 01/16/2024 | 01/18/2024 | |
|
Aziz Kabeer
Director |
Sell | 15,907 @ $19.65 | $312,573 | 377,542 | 01/16/2024 | 01/18/2024 | |
|
Adjuvant Global Health Technology Fund, L.P.
10 percent owner |
Sell | 84,093 @ $19.65 | $1.65 M | 1,995,958 | 01/16/2024 | 01/18/2024 | |
|
Adjuvant Global Health Technology Fund, L.P.
10 percent owner |
Sell | 15,907 @ $19.65 | $312,573 | 377,542 | 01/16/2024 | 01/18/2024 | |
|
Readnour Robin Shane
Director |
Sell | 719 @ $21.91 | $15,753 | 485,073 | 01/12/2024 | 01/17/2024 | |
|
Readnour Robin Shane
Director |
Sell | 706 @ $21.92 | $15,476 | 414,788 | 01/12/2024 | 01/17/2024 | |
|
Readnour Robin Shane
Director |
Sell | 1,800 @ $21.92 | $39,456 | 485,792 | 01/10/2024 | 01/12/2024 | |
|
Readnour Robin Shane
Director |
Sell | 1,869 @ $21.93 | $40,987 | 415,494 | 01/10/2024 | 01/12/2024 | |
|
Krause Kevin Michael
Chief Strategy Officer |
Sell | 7,417 @ $20.14 | $149,367 | 1,914 | 01/09/2024 | 01/11/2024 | |
|
Krause Kevin Michael
Chief Strategy Officer |
Sell | 2,583 @ $20.12 | $51,967 | 1,914 | 01/02/2024 | 01/04/2024 | |
|
Easom Eric
CEO |
Sell | 2,777 @ $20.09 | $55,802 | 2,130 | 01/02/2024 | 01/04/2024 | |
|
Adjuvant Global Health Technology Fund, L.P.
10 percent owner |
Sell | 1,522 @ $16.15 | $24,574 | 2,080,051 | 11/14/2023 | 11/16/2023 | |
|
Adjuvant Global Health Technology Fund, L.P.
10 percent owner |
Sell | 288 @ $16.15 | $4,650 | 393,449 | 11/14/2023 | 11/16/2023 | |
|
Aziz Kabeer
Director, 10 percent owner: |
Sell | 1,522 @ $16.15 | $24,574 | 2,080,051 | 11/14/2023 | 11/16/2023 | |
|
Aziz Kabeer
Director, 10 percent owner: |
Sell | 288 @ $16.15 | $4,650 | 393,449 | 11/14/2023 | 11/16/2023 | |
|
Aziz Kabeer
Director, 10 percent owner: |
Sell | 4,770 @ $16.07 | $76,654 | 2,081,573 | 10/02/2023 | 10/03/2023 | |
|
Aziz Kabeer
Director, 10 percent owner: |
Sell | 902 @ $16.07 | $14,495 | 393,737 | 10/02/2023 | 10/03/2023 | |
|
Adjuvant Global Health Technology Fund, L.P.
10 percent owner |
Sell | 4,770 @ $16.07 | $76,654 | 2,081,573 | 10/02/2023 | 10/03/2023 | |
|
Adjuvant Global Health Technology Fund, L.P.
10 percent owner |
Sell | 902 @ $16.07 | $14,495 | 393,737 | 10/02/2023 | 10/03/2023 |
AN2 Therapeutics, Inc. Frequently Asked Questions
-
Who is on AN2 Therapeutics, Inc.'s Insider Roster?
The list of insiders at AN2 Therapeutics, Inc. includes Easom Eric, Krause Kevin Michael, Readnour Robin Shane, Adjuvant Global Health Technology Fund, L.P., Aziz Kabeer, Zakrzewski Joseph S.
-
How much insider selling is happening at AN2 Therapeutics, Inc.?
Insiders have sold a total of 317,871 AN2 Therapeutics, Inc. shares in the last 12 months for a total of 6.21 M sold.
-
Which AN2 Therapeutics, Inc. insiders have been selling company stock?
The following insiders have sold AN2 Therapeutics, Inc. shares in the last 12 months: Easom Eric ($55,802), Krause Kevin Michael ($201,334), Readnour Robin Shane ($111,672), Adjuvant Global Health Technology Fund, L.P. ($1.97 M), Aziz Kabeer ($1.97 M), Zakrzewski Joseph S ($1.91 M),